- Previous Close
0.00 - Open
44.00 - Bid --
- Ask --
- Day's Range
44.45 - 44.45 - 52 Week Range
40.75 - 54.00 - Volume
100 - Avg. Volume
1 - Market Cap (intraday)
654.642M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.08 - Earnings Date Feb 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
www.basilea.comRecent News: BPMUF
View MorePerformance Overview: BPMUF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BPMUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BPMUF
View MoreValuation Measures
Market Cap
595.98M
Enterprise Value
651.97M
Trailing P/E
--
Forward P/E
11.38
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.90
Price/Book (mrq)
34.47
Enterprise Value/Revenue
3.87
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
37.21%
Return on Assets (ttm)
17.89%
Return on Equity (ttm)
218.58%
Revenue (ttm)
208.54M
Net Income Avi to Common (ttm)
77.59M
Diluted EPS (ttm)
-0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
120.71M
Total Debt/Equity (mrq)
137.87%
Levered Free Cash Flow (ttm)
48.68M